Diffusion Pharmaceuticals Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2023; filed May 15, 2023. The supplied filing is for Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), not Cervomed Inc. Financial statements are unaudited. Diffusion is a development-stage biopharmaceutical company; it reported no product revenue.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.31 million | $2.43 million; down $1.12 million |
| General and administrative expense | $2.96 million | $2.13 million; up $0.83 million |
| Operating loss | $4.27 million | $4.55 million |
| Interest income | $173,897 | $27,809 |
| Net loss | $4.09 million; $1.95 per share | $4.53 million; $2.22 per share |
| Net cash used in operating activities | $4.97 million | $4.73 million |
At March 31, 2023, cash and cash equivalents were $14.65 million, marketable securities were $2.99 million, and working capital was $16.4 million. Cash plus marketable securities totaled $17.6 million. Current liabilities were $2.13 million; the filing reports no debt. Accumulated deficit was $149.7 million. The company reported $16.28 million of stockholders’ equity.
Cash and cash equivalents increased $4.53 million during the quarter, principally because $9.5 million of marketable securities matured; operating activities used $4.97 million. This cash increase therefore did not reflect positive operating cash generation. Marketable securities had $3,333 of net unrealized losses at quarter-end; the company recorded no credit-loss allowance.
Changes versus the prior comparable period
- Net loss narrowed by approximately $0.43 million, despite operating cash use increasing by approximately $0.24 million.
- R&D expense declined, primarily reflecting lower project spending after completion or wind-down of certain TSC clinical and chemistry, manufacturing, and controls activities; the quarter also included severance costs.
- G&A expense rose, mainly due to professional fees associated with business-development activity. Interest income increased with higher interest rates.
- Cash and cash equivalents rose from $10.11 million at December 31, 2022, while marketable securities fell from $12.41 million to $2.99 million, largely reflecting maturities and reallocation to cash.
Business developments, outlook, and risks
- In March 2023, Diffusion agreed to merge with EIP Pharma. The transaction was pending and subject to closing conditions, including Diffusion stockholder approvals. If completed, former EIP holders were expected to own approximately 77.26% and pre-merger Diffusion holders approximately 22.74%, assuming specified closing net cash of $13.5–$14.5 million; actual ownership and net cash could differ.
- The combined company was expected to focus on central nervous system therapeutics, including EIP’s neflamapimod for dementia with Lewy bodies. EIP reported a $21 million NIH grant expected to fund clinical-trial costs for a planned Phase 2b study, which EIP anticipated starting by the end of Q2 2023. These are transaction-related expectations, not guaranteed outcomes.
- During Q1, the company reduced its 13-person workforce by seven and paused significant portions of TSC development, including the planned Phase 2 study in newly diagnosed glioblastoma patients. It said the workforce reduction was intended to preserve cash.
- Subject to the strategic review’s outcome and timing, and excluding the proposed merger, management expected available cash and marketable securities to fund current operations for at least 12 months after the report date. The company had no committed additional financing; it warned that unavailable funding could force further cuts, delayed or discontinued development, or cessation of operations. Future research, a merger, or another transaction may require additional funding.
- If the merger did not close, the company said it could pursue another strategic transaction, consider resuming TSC development if funding permitted, or dissolve and liquidate. A merger-related ownership change could limit use of tax-loss carryforwards.
- A longstanding former-CEO lawsuit remained unresolved. The company disputed the claims and could not estimate a possible loss; the filing says an adverse resolution could materially affect financial position, results, or cash flows. Trial was scheduled for October 25, 2023.
- Management concluded disclosure controls were effective at March 31, 2023 and reported no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Whether the EIP merger closed, its final terms, closing net cash, ownership split, and any required stockholder approvals.
- Cash runway and cash burn after Q1, including merger-related and other strategic-review expenses and the availability of additional financing.
- Whether TSC development remains paused and the status and funding of EIP’s planned neflamapimod Phase 2b study.
- Updates on the former-CEO litigation and any potential loss or settlement exposure.
- Potential dilution and capital structure changes; 2,040,025 common shares were outstanding at May 11, 2023, before any merger-related issuance.